Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Strata Skin Sciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 14.82%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Strata Skin Sciences's 3-Year ROIIC % or its related term are showing as below:
FRA:E2O's 3-Year ROIIC % is ranked better than 65.62% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 1.455
vs FRA:E2O: 14.82
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Strata Skin Sciences 3-Year ROIIC % Related Terms
Strata Skin Sciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:E2O vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Strata Skin Sciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's 3-Year ROIIC % falls into.
Strata Skin Sciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.983 (Dec. 2025) - -4.389 (Dec. 2022) )
/
( 29.602 (Dec. 2025) - 40.274 (Dec. 2022) )
=
-0.594
/
-10.672
=
5.57%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Strata Skin Sciences (FRA:E2O) has a 3-Year ROIIC % of 14.82 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Strata Skin Sciences and its competitors. According to the industry distribution chart, Strata Skin Sciences ranks #273 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 34.4%.
Is Strata Skin Sciences' 3-Year ROIIC % too high?
Strata Skin Sciences' current 3-Year ROIIC % is 14.82. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.46. Strata Skin Sciences' value of 14.82 is 918.6% above this industry median. Based on the distribution chart, Strata Skin Sciences ranks #273 out of 794 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #273 out of 794 companies for 3-Year ROIIC %. This puts Strata Skin Sciences in the upper half of its industry. The industry median 3-Year ROIIC % is 1.46. Strata Skin Sciences' value of 14.82 is 918.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.46, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current 3-Year ROIIC % of 14.82 is 918.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current 3-Year ROIIC % is 14.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current 3-Year ROIIC % of 14.82. The stock's GF Value™ is €1,526.56, compared to a current price of €3.76 — trading 99.8% below its estimated fair value. The current 3-Year ROIIC % is 14.82 and 918.6% above the Medical Devices & Instruments industry median of 1.46. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current 3-Year ROIIC % is 14.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 99.8% below its estimated GF Value™ of €1,526.56.
Key valuation signals for FRA:E2O:
3-Year ROIIC %: 14.82
GF Value™: €1,526.56 vs. price of €3.76 (99.8% below fair value)
Industry Position: 918.6% above the Medical Devices & Instruments median (#273 of 794)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
